L-(-)-α-Methyldopa hydrochlorideAlpha-adrenergic agonist CAS# 884-39-9 |
2D Structure
- BMS-708163 (Avagacestat)
Catalog No.:BCC2104
CAS No.:1146699-66-2
- DAPT (GSI-IX)
Catalog No.:BCC3618
CAS No.:208255-80-5
- YO-01027 (Dibenzazepine, DBZ)
Catalog No.:BCC2100
CAS No.:209984-56-5
- Semagacestat (LY450139)
Catalog No.:BCC3610
CAS No.:425386-60-3
- Flurizan
Catalog No.:BCC2342
CAS No.:51543-40-9
- E 2012
Catalog No.:BCC1540
CAS No.:870843-42-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 884-39-9 | SDF | Download SDF |
PubChem ID | 3083659 | Appearance | Powder |
Formula | C10H14ClNO4 | M.Wt | 247.68 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | (2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;hydrochloride | ||
SMILES | CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N.Cl | ||
Standard InChIKey | NLRUDGHSXOEXCE-PPHPATTJSA-N | ||
Standard InChI | InChI=1S/C10H13NO4.ClH/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6;/h2-4,12-13H,5,11H2,1H3,(H,14,15);1H/t10-;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
L-(-)-α-Methyldopa hydrochloride Dilution Calculator
L-(-)-α-Methyldopa hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.0375 mL | 20.1873 mL | 40.3747 mL | 80.7494 mL | 100.9367 mL |
5 mM | 0.8075 mL | 4.0375 mL | 8.0749 mL | 16.1499 mL | 20.1873 mL |
10 mM | 0.4037 mL | 2.0187 mL | 4.0375 mL | 8.0749 mL | 10.0937 mL |
50 mM | 0.0807 mL | 0.4037 mL | 0.8075 mL | 1.615 mL | 2.0187 mL |
100 mM | 0.0404 mL | 0.2019 mL | 0.4037 mL | 0.8075 mL | 1.0094 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
L-(-)-α-Methyldopa hydrochloride is an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive drug used as a sympatholytic or antihypertensive.
- Methyl syringate
Catalog No.:BCN4430
CAS No.:884-35-5
- AZD2932
Catalog No.:BCC6388
CAS No.:883986-34-3
- 8alpha-(2-Methylacryloyloxy)-1-O-methylhirsutinolide 13-O-acetate
Catalog No.:BCN7106
CAS No.:883872-71-7
- 8-Lavandulylkaempferol
Catalog No.:BCN3961
CAS No.:883859-83-4
- Adrenorphin
Catalog No.:BCC1021
CAS No.:88377-68-8
- DPDPE
Catalog No.:BCC5758
CAS No.:88373-73-3
- (9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
Catalog No.:BCN1316
CAS No.:883715-22-8
- N-Benzyloleamide
Catalog No.:BCN1317
CAS No.:101762-87-2
- N-Benzyllinolenamide
Catalog No.:BCN6531
CAS No.:883715-18-2
- E 64d
Catalog No.:BCC1127
CAS No.:88321-09-9
- BI 78D3
Catalog No.:BCC8089
CAS No.:883065-90-5
- CCG 50014
Catalog No.:BCC4897
CAS No.:883050-24-6
- 6,7-Dihydroxycoumarin-4-Acetic Acid
Catalog No.:BCC9205
CAS No.:88404-14-2
- Buparvaquone
Catalog No.:BCC5437
CAS No.:88426-33-9
- (E)-FeCP-oxindole
Catalog No.:BCC6078
CAS No.:884338-18-5
- Murraxocin
Catalog No.:BCN4431
CAS No.:88478-44-8
- Artesunate
Catalog No.:BCN2457
CAS No.:88495-63-0
- Manassantin A
Catalog No.:BCC8207
CAS No.:88497-87-4
- Farrerol 7-O-glucoside
Catalog No.:BCN6412
CAS No.:885044-12-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
- ARRY-520 R enantiomer
Catalog No.:BCC1368
CAS No.:885060-08-2
- ARRY 520 trifluoroacetate
Catalog No.:BCC2391
CAS No.:885060-09-3
- Dichotomitin
Catalog No.:BCN8524
CAS No.:88509-91-5
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
Interactions between iron(III)-hydroxide polymaltose complex and commonly used drugs / simulations and in vitro studies.[Pubmed:17691585]
Arzneimittelforschung. 2007;57(6A):360-9.
Under physiological conditions, ferric ions are essentially insoluble because of the formation of polynuclear hydroxo-bridged complexes. Ferrous ions are more soluble but may produce hydroxyl radicals on reaction with hydrogen peroxide. Chelation of ferric and ferrous ions with organic ligands may prevent these undesirable reactions. Alternatively, iron(III)-hydroxide/oxide can be stabilized and solubilized by tight interactions with carbohydrates. The data presented in this work show that, because of its physicochemical properties, the iron(III)-hydroxide polymaltose complex (IPC, Maltofer) does not interact with the active ingredients of commonly used drugs such as acetylsalicylic acid (CAS 50-78-2), tetracycline hydrochloride (CAS 64-75-5), calcium hydrogen-phosphate (CAS 7757-93-9), methyl-L-dopa sesquihydrate (CAS 41372-08-1), and magnesium-L-aspartate hydrochloride (CAS 28184-71-6). In contrast, as confirmed by calculations using thermodynamic parameters, FeCl3 x 6H2O (CAS 10025-77-1) can form different types of complexes with these substances. Moreover, the data show that under aerobic conditions high concentrations of ascorbic acid (CAS 50-81-7) can lead to mobilization of iron from IPC and, thus, support the observation that orange juice slightly increases the uptake of iron from IPC.
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.[Pubmed:24284262]
Eur Neuropsychopharmacol. 2014 Jan;24(1):148-59.
Depressed patients suffer from cognitive dysfunction, including memory deficits. Acute serotonin (5-HT) depletion impairs memory and mood in vulnerable patients. The investigational multimodal acting antidepressant vortioxetine is a 5-HT3, 5-HT7 and 5-HT1D receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and 5-HT transporter (SERT) inhibitor that enhances memory in normal rats in novel object recognition (NOR) and conditioned fear (Mork et al., 2013). We hypothesized that vortioxetine's 5-HT receptor mechanisms are involved in its memory effects, and therefore investigated these effects in 5-HT depleted rats. Four injections of the irreversible tryptophan hydroxylase inhibitor 4-chloro-dl-phenylalanine methyl ester hydrochloride (PCPA, 86mg/kg, s.c.) induced 5-HT depletion, as measured in hippocampal homogenate and microdialysate. The effects of acute challenge with vortioxetine or the 5-HT releaser fenfluramine on extracellular 5-HT were measured in PCPA-treated and control rats. PCPA's effects on NOR and spontaneous alternation (SA) performance were assessed along with the effects of acute treatment with 5-hydroxy-l-tryptophan (5-HTP), vortioxetine, the selective 5-HT reuptake inhibitor escitalopram, or the 5-HT norepinephrine reuptake inhibitor duloxetine. SERT occupancies were estimated by ex vivo autoradiography. PCPA depleted central 5-HT by >90% in tissue and microdialysate, and impaired NOR and SA performance. Restoring central 5-HT with 5-HTP reversed these deficits. At similar SERT occupancies (>90%) vortioxetine, but not escitalopram or duloxetine, restored memory performance. Acute fenfluramine significantly increased extracellular 5-HT in control and PCPA-treated rats, while vortioxetine did so only in control rats. Thus, vortioxetine restores 5-HT depletion impaired memory performance in rats through one or more of its receptor activities.
Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.[Pubmed:20669296]
Mov Disord. 2010 Sep 15;25(12):1881-7.
Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double-blind, double-dummy, controlled parallel group study, which compared the effectiveness of oral M/C effervescent tablets with standard oral formulation levodopa/carbidopa tablets (L/C; Sinemet) in reducing total daily OFF time. The difference of total daily OFF time (intention-to-treat population) between the two groups was not statistically significant (P = 0.07): -39.4 minutes (95%CI: -67.08 to -11.73) in M/C group vs. +3.5 minutes (95%CI: -36.19 to +43.26) in the L/C group. In the intragroup analysis, M/C significantly reduced the baseline daily OFF, which remained unchanged in the L/C group. There were no unexpected adverse events in either treatment arms, and discontinuation rates due to adverse events did not differ between the two groups [M/C: 2 patients (1.3%); L/C: 1 patient (1.4%)]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention.
Evaluation of drug-induced tissue injury by measuring alanine aminotransferase (ALT) activity in silkworm hemolymph.[Pubmed:23137391]
BMC Pharmacol Toxicol. 2012 Nov 8;13:13.
BACKGROUND: Our previous studies suggest silkworms can be used as model animals instead of mammals in pharmacologic studies to develop novel therapeutic medicines. We examined the usefulness of the silkworm larvae Bombyx mori as an animal model for evaluating tissue injury induced by various cytotoxic drugs. Drugs that induce hepatotoxic effects in mammals were injected into the silkworm hemocoel, and alanine aminotransferase (ALT) activity was measured in the hemolymph 1 day later. RESULTS: Injection of CCl4 into the hemocoel led to an increase in ALT activity. The increase in ALT activity was attenuated by pretreatment with N-acetyl-L-cysteine. Injection of benzoic acid derivatives, ferric sulfate, sodium valproate, tetracycline, amiodarone hydrochloride, methyldopa, ketoconazole, pemoline (Betanamin), N-nitroso-fenfluramine, and D-galactosamine also increased ALT activity. CONCLUSIONS: These findings indicate that silkworms are useful for evaluating the effects of chemicals that induce tissue injury in mammals.
Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications / laboratory studies in rats.[Pubmed:17691586]
Arzneimittelforschung. 2007;57(6A):370-5.
Simple iron salts, such as iron sulphate, often interact with food and other medications reducing bioavailability and tolerability. Iron(III)-hydroxide polymaltose complex (IPC, Maltofer) provides a soluble form of non-ionic iron, making it an ideal form of oral iron supplementation. The physicochemical properties of IPC predict a low potential for interactions. The effects of co-administration with aluminium hydroxide (CAS 21645-51-2), acetylsalicylic acid (CAS 50-78-2), bromazepam (CAS 1812-30-2), calcium acetate (CAS 62-54-4), calcium carbonate (CAS 471-34-1), auranofin (CAS 34031-32-8), magnesium-L-aspartate hydrochloride (CAS 28184-71-6), methyldopa sesquihydrate (CAS 41372-08-1), paracetamol (CAS 103-90-2), penicillamine (CAS 52-67-5), sulfasalazine (CAS 599-79-1), tetracycline hydrochloride (CAS 64-75-5), calcium phosphate (CAS 7757-93-9) in combination with vitamin D3 (CAS 67-97-0), and a multi-vitamin preparation were tested in rats fed an iron-deficient diet. Uptake of iron from radiolabelled IPC with and without concomitant medications was compared. None of the medicines tested had a significant effect on iron uptake. Iron-59 retrieval from blood and major storage organs was 64-76% for IPC alone compared with 59-85% following co-administration with other medications. It is concluded that, under normal clinical conditions, IPC does not interact with these medications.